Revenue and Scale
Q4 2025 revenue of $406.8M, up 4% year-over-year; Full-year 2025 revenue of $1,541.6M, up 0.5% YoY. Company impacted ~7 million patients in 2025.
Strategic M&A and Portfolio Expansion
Completed acquisitions to diversify radiodiagnostic portfolio including commercialized Neuraceq (beta-amyloid PET) and OCTEVY (neuroendocrine PET candidate), and announced divestiture of legacy SPECT business effective Jan 1, 2026 to focus on PET radiodiagnostics.
Neuraceq Commercial Traction
Neuraceq contributed $31M in Q4 2025 and $51.4M since acquisition in late July; company expects Neuraceq to grow triple digits inorganically in 2026 as manufacturing footprint expands (six additional PMF sites planned).
Market-Leading Products
PYLARIFY remains market-leading in PSMA PET (volume up ~4% YoY in Q4); DEFINITY delivered >$85M in Q4 and holds >80% market share, expected to grow low- to mid-single digits in 2026.
Late-Stage Pipeline and Potential Approvals
Multiple near-term regulatory milestones in 2026: new PSMA PET formulation (PDUFA Mar 6), OCTEVY (PDUFA Mar 29), PNT2003 (radioequivalent to Lutathera) with pending Hatch-Waxman litigation decision mid-year, and MK-6240 (tau PET; PDUFA Aug 13). Management expects material commercialization impact beginning in 2027.
2026 Financial Outlook
Guidance for 2026 worldwide net revenue of $1.40B–$1.45B, gross margin ~65.5%, R&D 10%–11% of revenue, and EPS guidance of $5.00–$5.25, reflecting planned investments and launch preparation.
Operational & Reimbursement Strategy
Clear launch playbook: regional rolling transition to new F-18 PSMA formulation in Q4 2026 with focus on coding, transitional pass-through status, payer coverage, and PMF network continuity to minimize supply disruption and drive 2027 growth.
Capital Return and Balance Sheet Actions
Completed $100M share repurchase in Q4 (1.77M shares) with $200M authorization remaining; cash & cash equivalents (net) of $359.1M at year-end.